Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin in HFpEF and Type 2 Diabetes
NCT04071626Phase 4Terminated
- Sponsor
- University Hospitals Cleveland Medical Center
- Start
- Mar 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) comparing Ertugliflozin Treatment Arm with Placebo (2 arms). Primary endpoint: Peak Exercise Oxygen Uptake at 12 weeks. Started Mar 2020; status: terminated.
02
Drugs
ertugliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04071626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04071626.